CDKN2A and neoplasm: In addition to previously well-known prognostic factors including performance status, KIT mutation, and tumor size, molecular biomarkers of low p16 and high p53 expressions were correlated with imatinib response and identified as significant and independent prognostic factors of PFS (43).